<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03039673</url>
  </required_header>
  <id_info>
    <org_study_id>H2020/PHRC-N/2014/GB-01</org_study_id>
    <secondary_id>No 633413</secondary_id>
    <secondary_id>PHRC-N, 14-0077, 2014</secondary_id>
    <secondary_id>Leigh/Jul15/971-797</secondary_id>
    <nct_id>NCT03039673</nct_id>
  </id_info>
  <brief_title>MIROCALS: Modifying Immune Response and OutComes in ALS</brief_title>
  <acronym>MIROCALS</acronym>
  <official_title>Efficacy and Safety of Low-dose IL-2 (Ld-IL-2) as a Treg Enhancer for Controlling Neuro-inflammation in Newly Diagnosed Amyotrophic Lateral Sclerosis (ALS) Patients: A Randomized, Double-blind, Placebo- Controlled, Phase-II Proof of Concept/ Proof of Mechanism Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      MIROCALS is a phase II study of ld-IL-2 as a therapeutic agent for ALS. A randomized (1:1),
      placebo-controlled, double-blind, parallel group trial will be carried out to assess ld-IL-2
      safety and clinical efficacy on survival and functional decline in newly diagnosed ALS
      patients treated for 18 months. Randomization will be stratified according to (i) country (n
      = 2 levels: UK, France) and (ii) site of onset (n= 2 levels: bulbar vs limb onset).

      The primary objective to evaluate the clinical efficacy and safety of the experimental drug
      (ld IL-2) over an 18 months period in order to establish the proof of concept (PoC) that
      modifying immune responses through the enhancement of regulatory T cells modifies the rate of
      ALS disease progression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The secondary objectives of MIROCALS are:

      To validate a new phase-II study design to improve the efficiency of drug development in ALS
      with early determination of drug response using established biomarkers (BMs).

      The aims of this new trial design are:

      (i) To shorten future trials duration in ALS using an early drug responding surrogate marker
      of disease activity; (ii) To establish the proof of mechanism (PoM) of the tested drugs;
      (iii) To identify drug responder status.

      Additional exploratory objectives are:

      (i) Deep immune &amp; inflammatory phenotyping (ii) Brain biomarkers (iii) Genomics and
      Transcriptomics
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 19, 2017</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to death from date of randomization to date of death</measure>
    <time_frame>Month 18</time_frame>
    <description>Time to death from date of randomization to date of death as documented in death certificates, or date of last documented news for patients lost to follow-up, or 548 days for patients who survive more than 548 days (censoring at 548 days). Death certificates are collected by the centre's principal investigator from the City Hall of the patients' home or birth place.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">216</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>low dose interleukin-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to this arm will receive subcutaneous injections of low-dose interleukin-2 in addition to oral Riluzole treatment.
Intervention: Riluzole Intervention: IL-2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients randomized to this arm will receive subcutaneious placebo injections (5% glucose water solution) in addition to oral Riluzole treatment.
Intervention: Riluzole Intervention: 5% glucose water solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riluzole</intervention_name>
    <description>All patients will be treated with Riluzole for a period of three months prior to final inclusion and randomization. Riluzole treatment will continue throughout the 18 months of follow-up planned for in this protocol.
Riluzole treatment is part of routine care for patients with ALS.</description>
    <arm_group_label>low dose interleukin-2</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IL-2</intervention_name>
    <description>The dose of IL-2 to be used in this study will be 2.0 million IU/day.
Each treatment course will last 5 days (i.e. 1 sub-cutaneous injection per day for 5 consecutive days). The 5-day course will be repeated every 4-weeks over an 18-month treatment period.
In case of intolerance, a flexible dose-reduction schedule is available.</description>
    <arm_group_label>low dose interleukin-2</arm_group_label>
    <other_name>low dose interleukin-2</other_name>
    <other_name>ultra low dose interleukin-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5% glucose water solution</intervention_name>
    <description>The placebo consists of 5% glucose water solution, which is the matrix with which low-dose IL-2 injections are prepared in the experimental arm. Placebo injections are prepared in exactly the same manner as IL-2 injections, just without the IL-2.
Each treatment course will last 5 days (i.e. 1 sub-cutaneous injection per day for 5 consecutive days). The 5-day course will be repeated every 4-weeks over an 18-month treatment period.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion criteria

          -  Patient is 18 years old and less than 76 years old

          -  Possible, Probable, Probable laboratory-supported or Definite ALS as defined by El
             Escorial Revised ALS diagnostic criteria

          -  Disease duration &lt;= 24 months

          -  Slow Vital capacity &gt;= 70% of normal

          -  No prior or present riluzole treatment

          -  Lumbar punctures accepted by patient and done

        Main Exclusion criteria

          -  Other neurodegenerative disease that could explain signs or symptoms

          -  Contra indication for lumbar puncture (history of allergy to xylocaine, presence of
             contra-indicated treatment, or coagulation test abnormality, clinically significant
             coagulopathy or thrombocytopenia)

          -  Non authorized treatment

          -  Other disease or disorders that could preclude functional assessment, or
             life-threatening disorders

          -  Any documented, active, past or present, auto-immune disorders except asymptomatic
             Hashimoto thyroiditis

          -  Using assisted ventilation

          -  Feeding through gastrostomy or nasogastric tube

          -  Women of child-bearing potential or sexually active man without contraception

          -  Pregnant or breast feeding woman

          -  Any clinically significant laboratory abnormality (excepting cholesterol,
             triglyceride, glucose, CK, ferritin)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nigel Leigh, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brighton and Sussex Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gilbert Bensimon, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Centre Hospitalier Universitaire de Nîmes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilbert Bensimon, MD, PhD</last_name>
    <email>gilbert.bensimon@psl.aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christine Payan, MD</last_name>
    <email>christine.payan@psl.aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHRU de Lille - Hôpital Roger Salengro</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr Véronique Danel, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges - Hôpital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Philippe Couratier, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HCL - Hôpital Neurologique P. Wertheimer</name>
      <address>
        <city>Lyon</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr Emilien Bernard, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHM - Hôpital de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>P Shahram Attarian, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Montpellier - Hôpital Gui de Chauliac</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>William Camu, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nice - Hôpital Pasteur</name>
      <address>
        <city>Nice</city>
        <zip>06002</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Claude Desnuelle, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP - Groupe Hospitalier Pitié-Salpetrière</name>
      <address>
        <city>Paris Cedex 13</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>François Salachas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CENTRE HOSPITALIER DE SAINT BRIEUC - Hôpital Yves Le Foll</name>
      <address>
        <city>Saint Brieuc</city>
        <zip>22027</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kolev Ivan, MD,PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Tours - Hôpital Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Philippe Corcia, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Trafford Centre for Biomedical Research</name>
      <address>
        <city>Brighton</city>
        <zip>BN1 9RY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>P Nigel Leigh, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North-East London and Essex MND Regional Care Centre</name>
      <address>
        <city>London</city>
        <zip>E1 4NS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andrea Malaspina, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King's MND Care and Research Centre</name>
      <address>
        <city>London</city>
        <zip>SE5 8AF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ammar Al-Chalabi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre for Neuromuscular Diseases - National Hospital of Neurology</name>
      <address>
        <city>London</city>
        <zip>WC1N 3BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dr Nikhil SHARMA, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheffield Care and Research Centre</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pamela J Shaw, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2017</study_first_submitted>
  <study_first_submitted_qc>January 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2017</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>interleukin-2</keyword>
  <keyword>low-dose interleukin-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
    <mesh_term>Riluzole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

